Cisbio Now Offers Custom Labeling Services For Fast, Cost-Effective, In-House Assay Development

Researchers now can access industry-leading turn around times and end-to-end technical support for drug discovery, research applications and screening programs.

Bedford, MA (PRWEB) - Cisbio US provides a total offering for researchers setting up in-house assays. The company has combined their custom labeling service, ready-to-use Toolbox reagents, and end-to-end technical support to provide fast and accurate labeling. Researchers can now quickly and cost-effectively develop and optimize assays for research applications and screening programs.

The company’s custom labeling service is noted for industry-leading turnaround times and competitive pricing. Researchers can label antibodies, large proteins, small peptides, or other biomolecules for HTRF® assays with europium and terbium donor cryptates, XL665 large molecule red acceptor, d2 small molecule red acceptor, G2 small molecule green acceptor, and Biotin and DNP tags. Cisbio can also label molecules used in high-content screening (HCS), fluorescence-activated cell sorting (FACS), or any application requiring high quality dyes and chemistry.

Cisbio offers multiple levels of custom services from labeling to complete assay development. Cisbio’s streamlined custom labeling process of consultation, labeling and delivery provides a fully-characterized, labeled biomolecule in microgram to gram quantities. Additionally, HTRF assay development is supported by a Cisbio technical resource assigned to the project until a working assay is fully optimized.

“Our 20 years of experience with HTRF allow us to provide delivery times and pricing not achievable by any other custom labeling service,” says Glenn Knapik, Vice President at Cisbio, US. “We know customers need to get an optimized assay up and running quickly. Our process and technical resources are focused on providing unparalleled service to our customers.”

Cisbio also provides ready-to-use assay kits and reagents for a wide range of biomarkers, GPCRs, and other biomolecules based on HTRF technology. Originally developed at Cisbio, HTRF combines fluorescence resonance energy transfer technology (FRET) with time-resolved measurement (TR) to provide a robust, simple homogeneous assay platform for drug discovery and other applications.

Cisbio US, Inc. is a subsidiary of Cisbio Bioassays.

About Cisbio
Cisbio Bioassays develops and markets products and technologies used for in vitro diagnostics and drug discovery. With its proprietary technology, HTRF, the company is a leader in homogeneous fluorescence detection methods, and offers first class assays and services for drug discovery researchers. In addition, Cisbio Bioassays provides a broad range of immunoassays for in vitro diagnostics, mainly tailored for cancerous pathologies, as well as metabolic and auto-immune diseases.

Based in Codolet, France, Cisbio Bioassays owns facilities in Bedford, MA, U.S.A., Shanghai, China and Tokyo, Japan and markets its global offer through a network of distributors. http://www.cisbio.com.